EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Price:
11.13 USD
-0.27%
Market Closed
Updated:
May 29, 2024
EyePoint Pharmaceuticals Inc
Total Receivables
|
EyePoint Pharmaceuticals Inc
Total Receivables Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Total Receivables
$3m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
6%
|
CAGR 10-Years
18%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Receivables
$14.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Receivables
$14.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Receivables
$15.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Receivables
$12.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Receivables
$10B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
See Also
What is EyePoint Pharmaceuticals Inc's Total Receivables?
Total Receivables
3m
USD
3m
USD
Based on the financial report for Mar 31, 2024, EyePoint Pharmaceuticals Inc's Total Receivables amounts to 3m USD.
What is EyePoint Pharmaceuticals Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
18%
18%
Over the last year, the Total Receivables growth was -71%. The average annual Total Receivables growth rates for EyePoint Pharmaceuticals Inc have been -37% over the past three years , 6% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
